WO2023036117A1 - Application de l-glutamine dans le traitement de l'ostéoarthrite - Google Patents
Application de l-glutamine dans le traitement de l'ostéoarthrite Download PDFInfo
- Publication number
- WO2023036117A1 WO2023036117A1 PCT/CN2022/117211 CN2022117211W WO2023036117A1 WO 2023036117 A1 WO2023036117 A1 WO 2023036117A1 CN 2022117211 W CN2022117211 W CN 2022117211W WO 2023036117 A1 WO2023036117 A1 WO 2023036117A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gln
- nkila
- tgf
- osteoarthritis
- glutamine
- Prior art date
Links
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 title claims abstract description 47
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 44
- 230000014509 gene expression Effects 0.000 claims abstract description 32
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims abstract description 22
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims abstract description 22
- 210000001612 chondrocyte Anatomy 0.000 claims abstract description 18
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims abstract description 6
- 230000037361 pathway Effects 0.000 claims abstract description 3
- 108020005198 Long Noncoding RNA Proteins 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 230000019491 signal transduction Effects 0.000 claims description 5
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 claims description 4
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 claims description 4
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 claims description 4
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 210000004940 nucleus Anatomy 0.000 claims description 4
- 102000034285 signal transducing proteins Human genes 0.000 claims description 4
- 108091006024 signal transducing proteins Proteins 0.000 claims description 4
- 102000003945 NF-kappa B Human genes 0.000 claims description 3
- 108010057466 NF-kappa B Proteins 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- 210000003917 human chromosome Anatomy 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 102000006240 membrane receptors Human genes 0.000 claims description 2
- 108020004084 membrane receptors Proteins 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract description 5
- 210000002744 extracellular matrix Anatomy 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 5
- 208000002193 Pain Diseases 0.000 abstract description 4
- 238000010171 animal model Methods 0.000 abstract description 3
- 230000030279 gene silencing Effects 0.000 abstract description 3
- 238000012226 gene silencing method Methods 0.000 abstract description 3
- 239000002876 beta blocker Substances 0.000 abstract description 2
- 230000003848 cartilage regeneration Effects 0.000 abstract description 2
- 230000006749 inflammatory damage Effects 0.000 abstract description 2
- 230000028709 inflammatory response Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 abstract description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 229940097320 beta blocking agent Drugs 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
- 210000003127 knee Anatomy 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 210000000629 knee joint Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 238000003032 molecular docking Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 238000012165 high-throughput sequencing Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000032170 Congenital Abnormalities Diseases 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 230000008407 joint function Effects 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000000111 isothermal titration calorimetry Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- YEYSQTFJKAWMNG-XMZRARIVSA-N (1r,2r)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol;n-(4-hydroxyphenyl)acetamide Chemical compound CC(=O)NC1=CC=C(O)C=C1.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 YEYSQTFJKAWMNG-XMZRARIVSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000024765 knee pain Diseases 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- NXZQLRDBZJJVLU-UHFFFAOYSA-N methyl 3-[methyl(nitroso)amino]propanoate Chemical compound COC(=O)CCN(C)N=O NXZQLRDBZJJVLU-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 description 1
- 229940079488 strontium ranelate Drugs 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the invention relates to the field of biomedicine, more specifically, it relates to the application of L-glutamine in the treatment of osteoarthritis.
- Osteoarthritis is the most common joint disease. It is the degeneration of articular cartilage caused by many factors such as strain, trauma, aging, congenital abnormalities of joints, and joint deformities. It is mainly characterized by the destruction of articular cartilage. Including synovial and chondrocyte inflammation, osteophyte formation and subchondral bone sclerosis and other pathological changes; the clinical manifestations are slowly developing joint pain, stiffness, joint swelling, limited mobility and joint deformity. Approximately 10%-20% of adults suffer from OA, thus imposing a huge socioeconomic burden.
- Non-drug treatment includes weight loss, aerobic training and physical therapy, etc., and is not aimed at the pathological state of the disease.
- Drug therapy is expected to improve the symptoms of patients and delay the pathological process of the disease.
- the current drugs for treating osteoarthritis are mainly anti-inflammatory and analgesic drugs, such as non-steroidal anti-inflammatory drugs, acetaminophen and tramadol, etc., which relieve symptoms but cannot delay the pathological process of osteoarthritis, but only delay the final operation time.
- DMOADs disease-modifying osteoarthritis drugs
- Its representative drugs include strontium ranelate, hydroxychloroquine, and tumor necrosis factor alpha blockers, etc., but these drugs are basically in the preclinical research stage, and their clinical efficacy is still uncertain and expensive.
- the object of the present invention is to provide the application of L-glutamine in the treatment of osteoarthritis.
- the technical purpose of the present invention is achieved through the following technical solutions: the application of L-glutamine in the preparation of medicines for treating osteoarthritis.
- the L-glutamine regulates the up-regulation of lncRNA NKILA gene expression through the TGF- ⁇ 1 signaling pathway to treat osteoarthritis.
- the expression of the lncRNA NKILA gene is up-regulated to reduce chondrocyte inflammatory damage by inhibiting NF- ⁇ B activation.
- the L-glutamine is combined with at least one of the alanine residue 230, leucine residue 278 and lysine residue 232 of TGF- ⁇ 1.
- the TGF- ⁇ 1 acts on the membrane receptor TGF- ⁇ R, it activates the downstream Smad2 and Smad3 signaling proteins, and the Smad2 and Smad3 signaling proteins enter the nucleus and bind to the NKILA promoter region to increase the expression of NKILA to prevent NF- ⁇ B activation and translocation into the nucleus.
- the lncRNA NKILA gene is located on human chromosome 20p13.
- the present invention has the following beneficial effects:
- the present invention uses L-Gln to treat rat OA animal models, and systematically evaluates the direct curative effect of L-Gln on OA from multiple aspects such as inflammatory response, extracellular matrix secretion, chondrocyte survival, and cartilage regeneration; combined with NKILA gene silencing And TGF- ⁇ receptor blockers and other methods revealed the molecular mechanism of L-Gln in the treatment of OA, and verified that L-Gln can up-regulate the expression of NKILA through the TGF- ⁇ 1 pathway, thereby inhibiting the activation of NF- ⁇ B and reducing the inflammation of chondrocytes damage, promote extracellular matrix secretion and cartilage repair, and provide a new theoretical basis for the prevention and treatment of OA; thus, L-Gln can be used as a new, cheap and more effective drug for improving osteoarthritis disease, not only can Relieve the pain caused by the patient's disease, and fundamentally improve the damaged cartilage structure, thereby delaying the progress of the disease.
- Fig. 1 is the knee joint KSS scoring result figure after L-Gln treatment in the embodiment of the present invention
- Fig. 2 is the expression spectrum of lncRNAs detected in human normal cartilage and OA cartilage by high-throughput sequencing method in the embodiment of the present invention
- Fig. 3 is the result figure of lncRNAs expression in OA cartilage and OA chondrocyte detected by Real-time PCR in the embodiment of the present invention
- Fig. 4 is a Docking result diagram of TGF- ⁇ 1, a potential target of L-glutamine in an example of the present invention.
- L-glutamine (L-glutamine, L-Gln) (trade name xinmaglin), the molecular formula is C5H10N2O3, it is a non-essential amino acid mainly concentrated in plasma and skeletal muscle, and plays an important role in human metabolism important regulatory role. Its structural formula is as follows:
- the knee joint OA models of rabbits and rats were established by anterior cruciate ligament resection, and the expression of NKILA in chondrocytes was detected by Real-time PCR, and it was found that NKILA was not expressed in rabbit chondrocytes , while the expression of rat chondrocytes, and the difference is roughly the same as the expression of human chondrocytes; finally, Real-time PCR was used to detect the expression of NKILA in rat OA chondrocytes cultured in vitro, and it was found that it was significantly lower than that of normal cartilage. The expression level of L-Gln was significantly increased after 10mM L-Gln.
- A is the expression of lncRNA in human OA chondrocytes cultured in vitro and its expression after adding L-Gln
- B is the expression of NKILA in human OA cartilage and rat OA cartilage
- C is the expression of human OA cartilage in vitro
- the experimental conditions are: 20mM PB, 100mM NaCl, 5% DMSO, pH 8.0, 18°C.
- concentrations of TGF- ⁇ 1 and L-Gln were 50 ⁇ M and 1000 ⁇ M, respectively.
- L-Gln exothermic after adding TGF- ⁇ 1, but did not reach saturation.
- DMSO was dropped into protein.
- L-Gln the exotherm continued, and the exotherm did not reach saturation.
- the present invention proposes for the first time that L-Gln up-regulates the expression of NKILA through the TGF- ⁇ 1 signaling pathway, thereby inhibiting the activation of the NF- ⁇ B signaling pathway, finally inhibiting the inflammatory injury and apoptosis of chondrocytes, promoting the secretion of extracellular matrix, and repairing damaged cells. Damaged articular cartilage to achieve the purpose of treating OA.
- the present invention respectively constructs OA cell models and animal models corresponding to NKILA gene silencing and TGF- ⁇ 1 blocking, revealing the molecular mechanism of L-Gln treating OA.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Une application de la L-glutamine dans le traitement de l'ostéoarthrite, qui concerne le domaine de la biomédecine, est divulguée. La présente invention utilise la L-Gln pour traiter un modèle animal de rat d'OA, et évalue systématiquement l'efficacité directe de la L-Gln sur l'OA en termes de réponse inflammatoire, de sécrétion de la matrice extracellulaire, de survie des chondrocytes, et de régénérescence du cartilage. En combinaison aux procédés tels que le silençage de gène NKILA et des agents bloquants le TGF-β, la L-Gln s'est montrée comme régulant à la hausse l'expression de NKILA par l'intermédiaire de la voie TGF-β1, inhibant ainsi l'activation du NF-κB, réduisant les dégâts inflammatoires des chondrocytes, et favorisant la sécrétion de la matrice extracellulaire et la réparation de cartilage. La L-Gln, comme nouveau médicament, bon marché, et plus efficace pour améliorer l'ostéoarthrite, non seulement soulage la douleur causée par la maladie, mais améliore également fondamentalement les structures du cartilage endommagé, ralentissant ainsi la progression de la maladie.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111043698.1A CN113768912A (zh) | 2021-09-07 | 2021-09-07 | L-谷氨酰胺在治疗骨关节炎中的应用 |
| CN202111043698.1 | 2021-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023036117A1 true WO2023036117A1 (fr) | 2023-03-16 |
Family
ID=78841631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2022/117211 WO2023036117A1 (fr) | 2021-09-07 | 2022-09-06 | Application de l-glutamine dans le traitement de l'ostéoarthrite |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113768912A (fr) |
| WO (1) | WO2023036117A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113768912A (zh) * | 2021-09-07 | 2021-12-10 | 安徽医科大学第二附属医院 | L-谷氨酰胺在治疗骨关节炎中的应用 |
| CN114796178A (zh) * | 2022-03-10 | 2022-07-29 | 李亚兰 | L-谷氨酰胺用于缓解银环蛇伤的潜在治疗用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113768912A (zh) * | 2021-09-07 | 2021-12-10 | 安徽医科大学第二附属医院 | L-谷氨酰胺在治疗骨关节炎中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1663283B1 (fr) * | 2003-09-12 | 2012-05-23 | University of Colorado | Glutamine pour le traitement de lesion |
-
2021
- 2021-09-07 CN CN202111043698.1A patent/CN113768912A/zh active Pending
-
2022
- 2022-09-06 WO PCT/CN2022/117211 patent/WO2023036117A1/fr active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113768912A (zh) * | 2021-09-07 | 2021-12-10 | 安徽医科大学第二附属医院 | L-谷氨酰胺在治疗骨关节炎中的应用 |
Non-Patent Citations (3)
| Title |
|---|
| FUJITA SHINYA, ARAI YUJI, NAKAGAWA SHUJI, TAKAHASHI KENJI A., TERAUCHI RYU, INOUE ATSUO, TONOMURA HITOSHI, HIRAOKA NOBUYUKI, INOUE: "Combined microwave irradiation and intraarticular glutamine administration-induced HSP70 expression therapy prevents cartilage degradation in a rat osteoarthritis model", JOURNAL OF ORTHOPAEDIC RESEARCH, ORTHOPAEDIC RESEARCH SOCIETY, US, vol. 30, no. 3, 18 August 2011 (2011-08-18), US , pages 401 - 407, XP093045601, ISSN: 0736-0266, DOI: 10.1002/jor.21535 * |
| TONOMURA, H. TAKAHASHI, K.A. MAZDA, O. ARAI, Y. INOUE, A. TERAUCHI, R. SHIN-YA, M. KISHIDA, T. IMANISHI, J. KUBO: "Glutamine protects articular chondrocytes from heat stress and NO-induced apoptosis with HSP70 expression", OSTEOARTHRITIS AND CARTILAGE, ELSEVIER, AMSTERDAM, NL, vol. 14, no. 6, 1 June 2006 (2006-06-01), AMSTERDAM, NL, pages 545 - 553, XP005454341, ISSN: 1063-4584, DOI: 10.1016/j.joca.2005.12.008 * |
| YANG, K. C. ET AL.: "L-glutamine regulates the expression of matrix proteins, pro-inflammatory cytokines and catabolic enzymes in interleukin-1beta-stimulated human chondrocytes", PROCESS BIOCHEMISTRY, vol. 51, 19 December 2015 (2015-12-19), XP029422123, DOI: 10.1016/j.procbio.2015.12.010 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113768912A (zh) | 2021-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023036117A1 (fr) | Application de l-glutamine dans le traitement de l'ostéoarthrite | |
| TWI283177B (en) | New use of neurotoxin for treating thyroid and calcemia disorders | |
| CN104127859B (zh) | 多肽在制备治疗或预防类风湿性关节炎药物中的应用 | |
| Ni et al. | Immune-responsive gene 1/itaconate activates nuclear factor erythroid 2-related factor 2 in microglia to protect against spinal cord injury in mice | |
| JP2020152698A5 (fr) | ||
| Barreto et al. | A new treatment for knee osteoarthritis: Clinical evidence for the efficacy of Arthrokinex™ autologous conditioned serum | |
| JP2010168403A (ja) | ストレプトリジンｏを用いた末梢動脈障害に起因する跛行の治療 | |
| CN104903344B (zh) | Pedf衍生的多肽在治疗骨关节炎中的用途 | |
| Cheng et al. | The role of mitochondrial energy metabolism in neuroprotection and axonal regeneration after spinal cord injury | |
| Wang et al. | A discovery of clinically approved Panlongqi Tablet for repositioning to treat osteoarthritis by inhibiting PI3K/AKT activation | |
| Umławska et al. | Growth retardation and delayed puberty in children and adolescents with juvenile idiopathic arthritis | |
| Al-Sammarraie et al. | Neuroprotective role of Noggin in spinal cord injury | |
| CN115605215A (zh) | 改善或减轻线粒体功能损伤的治疗 | |
| Cuevas et al. | Fibroblast growth factor: A target for Covid-19 infection | |
| Teng et al. | Prelude to the special issue on novel neurocircuit, cellular and molecular targets for developing functional rehabilitation therapies of neurotrauma | |
| WO2016066068A1 (fr) | Utilisation d'une formulation composite de métallothionéine en tant que médicament pour le traitement des séquelles d'accident vasculaire cérébral par entrée par points d'acupuncture | |
| CN118812453B (zh) | 一种组蛋白去乙酰化酶6抑制剂及其制备和在治疗缺血性卒中的应用 | |
| TW202019457A (zh) | 新的肌肉因子及其用途 | |
| Karmakar et al. | Targeting the NLRP3 inflammasome as a novel therapeutic target for osteoarthritis | |
| Zhang et al. | Targeting astrocytic TDAG8 with delayed CO2 postconditioning improves functional outcomes after controlled cortical impact injury in mice | |
| Liu et al. | Neuroprotection of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in alleviating ischemic stroke-induced brain injury by regulating inflammation and oxidative stress | |
| Yao | Intra-articular Injection of Magnesium-containing Solution as an Effective Strategy for Alleviating Osteoarthritis: A Proof-of-Concept Study | |
| RU2811435C2 (ru) | Рекомбинантные модифицированные факторы роста фибробластов и их терапевтическое применение | |
| US20240398792A1 (en) | Therapeutic agent composition and method of use, for treating, relieving, or alleviating alzheimer's disease | |
| Fu et al. | Effect of tubastatin a on the functional recovery of cauda equina injury in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22866580 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 22866580 Country of ref document: EP Kind code of ref document: A1 |